Cholesterol, Coronary Heart Disease and Stroke: A Review of Published Evidence from Observational Studies and Randomized Controlled Trials

 

 Buy Article Permissions and Reprints

ABSTRACT

In observational epidemiologic studies, lower blood cholesterol is associated with a reduced risk from coronary heart disease (CHD) throughout the normal range of cholesterol values observed in most Western populations. There is a continuous positive relationship between CHD risk and blood cholesterol down to at least 3 to 4 mmol/l, with no threshold below which a lower cholesterol is not associated with a lower risk. Observational studies suggest that a prolonged difference in total cholesterol of about 1 mmol/l is associated with one-third less CHD deaths in middle age. Evidence from large-scale cholesterol lowering trials in patients at high-risk of CHD have demonstrated that much of the epidemiologically predicted difference in CHD risk associated with differences in cholesterol was achieved within a few years of treatment. Moreover, these trials have demonstrated that such therapy was not associated with increased non-CHD mortality. Total cholesterol is transported in blood as low-density lipoprotein cholesterol or LDL cholesterol (about 70%) and as high density lipoprotein cholesterol or HDL cholesterol (about 30%). Since these two cholesterol fractions have opposing effects on vascular risk, a 1 mmol/l reduction in LDL cholesterol is likely to be associated with 40 to 50% lower CHD risk. The size of the absolute reduction in CHD produced by lowering total and LDL cholesterol is determined by an individual's overall risk rather than their initial cholesterol level. Consequently, the benefits of drug treatment to lower LDL cholesterol are greater in those at higher absolute risk of CHD rather than at high cholesterol levels. Dietary saturated fat is the chief determinant of total and LDL cholesterol levels. Replacing 60% of the intake of saturated fat by other fats and reducing the intake of dietary cholesterol could reduce blood total cholesterol levels by about 0.8 mmol/l (that is by 10 to 15%), with four fifths of this reduction being in LDL cholesterol.

REFERENCES

• 1 Peto R, Lopez A D, Boreham J. Mortality from smoking in developed countries 1950-2000. 1994. Oxford, Oxford University Press
  Google Scholar
• 2 Martin M J, Hulley S B, Browner W S. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men.  Lancet . 1986;  2 933-936
  PubMedGoogle Scholar
• 3 Verschuren W M, Jacobs D R, Bloemberg B P. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study.  JAMA . 1995;  274 131-136
  CrossrefPubMedGoogle Scholar
• 4 Law M R, Wald N J, Wu T. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study.  BMJ . 1994;  308 363-366
  PubMedGoogle Scholar
• 5 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 344: 1383-1389
  Google Scholar
• 6 Sacks F M, Pfeffer M A, Moye L A. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators.  N Engl J Med . 1996;  335 1001-1009
  CrossrefPubMedGoogle Scholar
• 7 Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998 339: 1349-1357
  Google Scholar
• 8 Downs J R, Clearfield M, Weis S. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.  JAMA . 1998;  279 1615-1622
  CrossrefPubMedGoogle Scholar
• 9 Miller G J, Miller N E. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease.  Lancet . 1975;  1 16-19
  PubMedGoogle Scholar
• 10 Ross R. The pathogenesis of atherosclerosis-an update.  N Engl J Med . 1986;  314 488-500
  CrossrefPubMedGoogle Scholar
• 11 Keys A. Seven Countries: A multivariable analysis of death and coronary heart disease. 1980. Harvard University Press, Cambridge
  Google Scholar
• 12 Keys A G F J. Prediction of serum-cholesterol responses of man to changes in fats in the diet.  Lancet . 1957;  ii 959-966
  PubMedGoogle Scholar
• 13 Hegsted D M, Ausman L M, Johnson J A. Dietary fat and serum lipids: an evaluation of the experimental data.  Am J Clin Nutr . 1993;  57 875-883
  PubMedGoogle Scholar
• 14 Brown M S, Goldstein J L. A receptor-mediated pathway for cholesterol homeostasis.  Science . 1986;  232 34-47
  CrossrefPubMedGoogle Scholar
• 15 Breslow J L. Human apolipoprotein molecular biology and genetic variation.  Annu Rev Biochem . 1985;  54699-54727
  PubMedGoogle Scholar
• 16 Mahley R W, Innerarity T L, Rall S C. Plasma lipoproteins: apolipoprotein structure and function.  J Lipid Res . 1984;  25 1277-1294
  PubMedGoogle Scholar
• 17 Moorjani S, Roy M, Torres A. Mutations of low-density-lipoprotein-receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolaemia.  Lancet . 1993;  341 1303-1306
  CrossrefPubMedGoogle Scholar
• 18 Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis 1999 142: 105-112
  Google Scholar
• 19 Steinberg D, Parthasarathy S, Carew T E. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.  N Engl J Med . 1989;  320 915-924
  CrossrefPubMedGoogle Scholar
• 20 GISSI Prevenzionne Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarcto miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI Prevenzione trial. Lancet 1999 354: 447-455
  Google Scholar
• 21 Ascherio A, Rimm E B, Giovannucci E L. Dietary fat and risk of coronary heart disease in men: cohort follow up study in the United States.  BMJ . 1996;  313 84-90
  CrossrefPubMedGoogle Scholar
• 22 Pietinen P, Ascherio A, Korhonen P. Intake of fatty acids and risk of coronary heart disease in a cohort of Finnish men. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study.  Am J Epidemiol . 1997;  145 876-887
  PubMedGoogle Scholar
• 23 Clarke R, Frost C, Collins R. Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies.  BMJ . 1997;  314 112-117
  PubMedGoogle Scholar
• 24 Tang J L, Armitage J M, Lancaster T. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects.  BMJ . 1998;  316 1213-1220
  PubMedGoogle Scholar
• 25 Hooper L, Summerbell C D, Higgins J P. Dietary fat intake and prevention of cardiovascular disease: systematic review.  BMJ . 2001;  322 757-763
  CrossrefPubMedGoogle Scholar
• 26 Clarke R, Shipley M, Lewington S. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies.  Am J Epidemiol . 1999;  150 341-353
  CrossrefPubMedGoogle Scholar
• 27 MacMahon S, Peto R, Cutler J. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias.  Lancet . 1990;  335 765-774
  CrossrefPubMedGoogle Scholar
• 28 Clarke R, Lewington S, Youngman L. Underestimation of the importance of blood pressure and cholesterol for CHD mortality in old age.  Eur Heart J . 2002;  23 286-293
  CrossrefPubMedGoogle Scholar
• 29 Peto R, Yusuf S, Collins R. Cholesterol lowering trials in their epidemiologic context.  Circulation . 1985;  72 451
  PubMedGoogle Scholar
• 30 Collins R, Keech A, Peto R. Cholesterol and total mortality: need for larger trials.  BMJ . 1992;  304 1689
  PubMedGoogle Scholar
• 31 Davey-Smith G,.Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs?.  BMJ . 1992;  304 431-434
  PubMedGoogle Scholar
• 32 Oliver M F. Is cholesterol reduction always safe?.  Eur J Clin Invest . 1992;  22 441-442
  PubMedGoogle Scholar
• 33 The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl J Med 1997 336: 153-162
  Google Scholar
• 34 Shepherd J, Cobbe S M, Ford I. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.  N Engl J Med . 1995;  333 1301-1307
  CrossrefPubMedGoogle Scholar
• 35 Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). Ital Heart J 2000 1: 810-820
  Google Scholar
• 36 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial.  Lancet . 2002;  306 7-22
  PubMedGoogle Scholar
• 37 Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet 1998 352: 1801-1807
  Google Scholar
• 38 Prospective Studies Collaboration. Collaborative overview (`meta-analysis') of prospective observational studies of the associations of usual blood pressure and usual cholesterol levels with common causes of death: protocol for the second cycle of the Prospective Studies Collaboration.  J Cardiovasc Risk . 1999;  6 315-320
  PubMedGoogle Scholar
• 39 Cholesterol Treatment Trialists' Collaboration. Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens.  Am J Cardiol . 1995;  75 1130-1134
  CrossrefPubMedGoogle Scholar